Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 2/20 | 0.30 |
| ▸ | ALB | P02768 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29666465 | 1.00 | EGLN2 (0.33) | EGLN2TTRALBMEN1KMT2A | |
| SCHEMBL2011602 | 0.77 | TTR (0.40) | EGLN2TTRALBMEN1KMT2A | |
| SCHEMBL816745 | 0.77 | PDE2A (0.37) | — | |
| SCHEMBL9312777 | 0.77 | PDE2A (0.37) | — | |
| SCHEMBL3182180 | 0.77 | TTR (0.40) | EGLN2TTRALBMEN1KMT2A | |
| SCHEMBL29666405 | 0.75 | TTR (0.39) | TTRALBMEN1KMT2A | |
| SCHEMBL21588073 | 0.75 | TTR (0.39) | TTRALBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL9495207 | 0.74 | TTR (0.39) | EGLN2TTRALBMEN1KMT2A | |
| SCHEMBL21588237 | 0.73 | KIF11 (0.42) | — | |
| SCHEMBL933868 | 0.71 | MAP4K4 (0.41) | EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234226-B2 | Compounds as nuclear transport modulators and uses thereof | XWPharma Ltd. (KY) | 2025-02-25 | — | — | US | disclosed |
| EP-3802501-B1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPHARMA LTD (KY) | 2024-02-28 | — | — | EP | disclosed |
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-09-28 | — | — | US | disclosed |
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XWPharma Ltd. (KY) | 2023-09-26 | — | — | US | disclosed |
| CN-115089586-A | Compounds as nuclear transport modulators and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-112566902-B | Compounds as nuclear transport modulators and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-112566902-A | Compounds as nuclear transport modulators and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-20210087177-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-03-25 | — | — | US | disclosed |
| WO-2019233447-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XW LABORATORIES, INC. (CN) | 2019-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234226-B2 | Compounds as nuclear transport modulators and uses thereof | XPOT, XPO1, XPO5 | EGLN2 2341/4885TTR 3757/4885ALB 4813/4885 |
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XPOT, XPO1, XPO5 | EGLN2 2341/4885TTR 3757/4885ALB 4813/4885 |
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPOT, XPO1, XPO5 | EGLN2 2341/4885TTR 3757/4885ALB 4813/4885 |
| US-20210087177-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPOT, XPO1, XPO5 | EGLN2 2341/4885TTR 3757/4885ALB 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.